Subscribe To
Gracell biotechnologies to participate in four upcoming investor conferences
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDA...
November 1, 2023, 4:00 pm
Uk regulator approves pfizer's hair loss drug
Britain's medicines regulator on Wednesday approved Pfizer Inc's drug to treat hair loss caused by an autoimmu...
November 1, 2023, 7:39 am
Argenx to present at upcoming investor conferences
November 1, 2023 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of peop...
November 1, 2023, 2:00 am
Abbvie results beat expectations despite low-cost competition to blockbuster humira
AbbVie Inc. ABBV, -0.04% on Friday reported third-quarter sales and profit that topped analyst expectations and raised its full-year earnings outlook,...
October 27, 2023, 7:42 am
Fate therapeutics to webcast conference call reporting third quarter 2023 financial results
SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage ...
October 25, 2023, 8:00 am
Argenx to report third quarter 2023 financial results and business update on october 31, 2023
October 24, 2023 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of peop...
October 24, 2023, 1:00 am
Argenx: efgartigimod is not just a drug, a cornerstone
argenx exhibits robust financials with a Q2 YoY net sales surge to $269.3M and liquidity of $2.0B but faces increasing operating costs and R&D expendi...
October 17, 2023, 1:07 am
Alpine immune sciences to present initial clinical data on povetacicept in autoimmune glomerulonephritis in a late breaker poster session at american society of nephrology kidney week 2023
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative...
October 13, 2023, 9:05 am
Sana biotechnology announces increased focus on hypoimmune-related pipeline with the potential to deliver clinical proof of concept data from four programs in 2023 and 2024 with a 2024 operating burn
Increasing focus on ex vivo cell therapy platform based on extensive preclinical and early translational clinical data suggesting ability of hypoimmun...
October 10, 2023, 8:15 pm
Why shares of ventyx biosciences are dropping tuesday
Ventyx is a clinical-stage biotech that focuses on autoimmune disorders. The company's lead therapy can...
October 10, 2023, 12:55 pm
Alpine immune sciences: november 2023 data release could get ball rolling
Preliminary clinical data from the Alpine Immune Sciences, Inc. ongoing phase 3 RUBY-3 study will be presented at the American Society of Nephrology A...
October 6, 2023, 3:31 pm
Iqvia (iqv) and argenx partner to advance autoimmune care
IQVIA (IQV) and argenx expand collaboration to advance rare autoimmune treatments through innovative ph...
October 5, 2023, 9:46 am
Immunovant announces closing of upsized common stock financing and full exercise of underwriters’ option to purchase additional shares
NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives f...
October 2, 2023, 8:52 pm
Exagen announces acceptance of multiple abstracts at acr 2023 annual meeting
SAN DIEGO, California, Sept. 28, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of au...
September 28, 2023, 8:05 pm
Biohaven (bhvn) up on positive data from autoimmune disease drug
Biohaven (BHVN) gains on preliminary data from a pre-clinical study on its pipeline candidate BHV-1300 targeting various ...
September 28, 2023, 9:01 am
Immunovant announces pricing of $450 million common stock financing
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives ...
September 28, 2023, 3:41 am
Why immunovant stock is bolting higher today
Tuesday, Immunovant announced early-stage trial results for an autoimmune disease candidate that caused...
September 27, 2023, 12:21 pm
Why shares of allakos are up wednesday
An analyst's recommendation may have helped boost Allakos stock. Allakos has two lead therapies to treat autoi...
September 27, 2023, 12:10 pm
Why biohaven stock is skyrocketing today
Biohaven released a new investor presentation that featured encouraging information about drug candidate BHV-1300. The experimental drug showed promis...
September 27, 2023, 12:00 pm
Akari therapeutics to present at emerging growth conference
BOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced t...
September 27, 2023, 8:00 am